The first coronavirus vaccine to be tested in people appears to be safe and able to stimulate an immune response against the virus, its manufacturer, Moderna, announced on Monday.
The findings are based on results from the first eight people who each received two doses of the vaccine, starting in March.
Those people, healthy volunteers, made antibodies that were then tested in human cells in the lab, and were able to stop the virus from replicating — the key requirement for an effective vaccine. The levels of those so-called neutralizing antibodies matched the levels found in patients who had recovered after contracting the virus in the community.
The company has said that it is proceeding on an accelerated timetable, with the next phase involving 600 people to begin soon. But U.S. government officials have warned that producing a vaccine that would be widely available could take a year to 18 months. There is no proven treatment or vaccine against the coronavirus at this time.
If the trials go well, a vaccine could become available for widespread use by the end of this year or early 2021, Moderna’s chief medical officer said.
The Connyak BBS